Subscribe To

Price Alert Latest News Economic Calendar News

KPTI / Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting

– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable Tolerability with No Dose Limiting Toxicities and 75% of Evaluable Patients Demonstrating ≥35% Spleen Volume Reduction (SVR 35) at Week 12 – – FDA Grants Orphan Drug Designation for Selinexor for the Treatment of Myelofibrosis – – Exploratory Subgroup Analyses from SIENDO Trial in Patients with Endometrial Cancer Treated with Selinexor as Maintenance Therapy Identified p53 Wild-type as a Potentially Important Predictor of Efficacy, with 10-month PFS Improvement over Placebo; No Benefit Was Seen in Patients with p53 Mutant Tumors – NEWTON, Mass., May 26, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced promising initial data from a Phase 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naïve myelofibrosis and subgroup analyses and molecular classification data from the SIENDO study evaluating selinexor in endometrial cancer. Read More

Demo Live Account See Partner Details

Content Topics

Karyopharm

Present

Selinexor

Data

2022

American

Society

Clinical

Oncology

Annual

Meeting

Stock

KPTI

Posted: May 26 2022, 17:08

Author Name: PRNewsWire

KPTI News

By Seeking Alpha
November 2, 2023

Karyopharm Therapeutics Inc. (KPTI) Q3 2023 Earnings Conference Call Transcript

Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Ric

By Zacks Investment Research
August 2, 2023

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares

By InvestorPlace
July 18, 2023

Why Is Karyopharm Therapeutics (KPTI) Stock Up 21% Today?

Karyopharm Therapeutics (NASDAQ: KPTI ) stock is climbing higher on Tuesday after getting fast-track designation for its myelofibrosis treatment. The

By Zacks Investment Research
July 5, 2023

All You Need to Know About Karyopharm Therapeutics (KPTI) Rating Upgrade to Buy

Karyopharm Therapeutics (KPTI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #

By Seeking Alpha
May 6, 2023

Karyopharm Therapeutics, Inc. (KPTI) Q1 2023 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR Richard

By Zacks Investment Research
May 4, 2023

Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue Estimates

Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares

By Seeking Alpha
March 20, 2023

Karyopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma Market

Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, ther

By Seeking Alpha
February 15, 2023

Karyopharm Therapeutics, Inc. (KPTI) Q4 2022 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI ) Q4 2022 Earnings Conference Call February 15, 2023 8:00 AM ET Company Participants Elhan Webb - SVP, IR R

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.